ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 1897

Changes in SLE Mortality During and After the COVID-19 Pandemic
Abstract Number: 1898

Assessing Representation in a Nation-Wide Psoriasis Registry: A Single-Institution Comparison
Abstract Number: 1899

Regional Variability in SLE Damage Accumulation by Disease Activity Across the Lupus Federated Data Network (LupusNet)
Abstract Number: 1900

Capturing Patient Cohorts: A Temporal Arteritis Classifier
Abstract Number: 1901

Epidemiology of Adult-Onset Still’s Disease in South Korea: A Nationwide Study Using Health Insurance Claims Data
Abstract Number: 1902

Investigating Factors Associated With Respiratory Syncytial Virus Vaccination and Breakthrough Infection Among Patients With Systemic Autoimmune Rheumatic Diseases
Abstract Number: 1903

Seasonal and Racial/Ethnic Variation in Achieving Target Uric Acid Levels in Gout Patients on Urate Lowering Therapy in US Veterans in Central California
Abstract Number: 1904

Mapping CTD-ILD in a Spanish Cohort – the NIRRVANA Registry
Abstract Number: 1905

Exploring the Association Between Environmental Quality Index and Rheumatoid Arthritis Mortality in the United States
Abstract Number: 1906

The incidence and mortality of connective tissue diseases in England: a population-level cohort study from 2012 to 2023
Abstract Number: 1907

Twenty-Year Trends in the U.S. Burden of Gout: A State-Level Analysis of Disability and Prevalence from 2001 to 2021
Abstract Number: 1908

Clinical and Imaging Features of Haemochromatosis Arthropathy – a Systematic Literature Review and Meta- Analysis
Abstract Number: 1909

Trends of venous thromboembolism after total joint replacement in the United Kingdom after the introduction of NICE guidelines.
Abstract Number: 1910

Clinical profile and healthcare resource utilization of patients diagnosed with giant cell arteritis or polymyalgia rheumatica in the US: a real-world cohort study using a large database of administrative health claims
Abstract Number: 1911

Characterizing Psoriasis Patients at Risk for Transition to Psoriatic Arthritis: Early Insights from the STOP PsA At-Risk Cohort

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].